Timing of immunotherapy for advanced cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) or another advanced solid tumor
- You are about to start or continue a type of immunotherapy called a PD-1/PD-L1 inhibitor (like Keytruda or Tecentriq)
- You have not had immunotherapy before (unless you are in a group continuing after initial treatment)
- You are willing to have your treatment times set by the study—either early morning or later in the day
- You can read and write in English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
This study compares getting your standard pembrolizumab (Keytruda) infusion in the morning versus at different times of day. It tests whether the timing of your treatment influences how well it works or how you feel.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
This trial tests whether giving immunotherapy (nivolumab and ipilimumab) at a specific time of day can improve survival in people with advanced kidney cancer. It compares infusions before 11:30 a.m. versus after 1:30 p.m.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
Hear when a new Advanced/Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.